
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABUS | NASDAQ | USD | Real-time | |
I9DN | Frankfurt | EUR | Delayed | |
I9DN | TradeGate | EUR | Delayed |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Lindsay Androski | 52 | 2025 | Interim President, CEO & Director |
William T. Symonds | 57 | 2015 | Chairman of Scientific Advisory Board |
Joseph Bishop | - | 2025 | Director |
Robert Alan Beardsley | 63 | 2025 | Independent Director |
Matthew Gline | 41 | 2025 | Independent Director |
Roger A. Sawhney | 55 | 2025 | Director |
Jordan J. Feld | - | 2025 | Member of Scientific Advisory Board |
Mark Sulkowski | - | 2025 | Member of Scientific Advisory Board |
Man-Fung Yuen | - | 2025 | Member of Scientific Advisory Board |
Edward J. Gane | - | 2025 | Member of Scientific Advisory Board |
Anna Suk-fong Lok | - | 2025 | Member of Scientific Advisory Board |
Harry Janssen | - | 2025 | Member of Scientific Advisory Board |
Ulrike Protzer | - | - | Member of Scientific Advisory Board |
Charles M. Rice | - | - | Member of Scientific Advisory Board |
Scott A. Biller | 69 | - | Member of Scientific Advisory Board |
Kyong-Mi Chang | - | - | Member of Scientific Advisory Board |
Fabien Zoulim | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review